AVRX Avalon Pharmaceuticals (MM)

GERMANTOWN, Md., Oct. 30 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX)(NYSE:AVRX), a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that Kenneth C. Carter, Ph.D., President and CEO, is scheduled to provide an update on the Company at the 2006 Susquehanna Financial Group Emerging Trends Conference. The meeting will be held at the Peninsula Hotel in New York City on November 1, 2006. Dr. Carter is scheduled to present on Wednesday, November 1st at 1:30 p.m., EST, in the Greenwich Room. A live audio webcast of this presentation can be accessed on Avalon Pharmaceuticals' website, http://www.avalonrx.com/ and a replay of the presentation will be available for 90 days following the conference. About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics through the use of a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis which it calls AvalonRx(R). This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response. Avalon's focus is oncology but the company has discovery programs in other therapeutic areas with partners. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Maryland. Contacts: Avalon Pharmaceuticals, Inc. Noonan Russo Gary Lessing Wendy Lau (Media) Executive Vice President & CFO Tel: (212) 845-4272 Tel: (301) 556-9900 Fax: (301) 556-9910 The Trout Group LLC Email: Chad Rubin (Investors) Tel: (212) 477-9007 ext. 47 DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing, Executive Vice President & CFO of Avalon Pharmaceuticals, Inc., +1-301-556-9900, fax: +1-301-556-9910, ; or Media: Wendy Lau of Noonan Russo, +1-212-845-4272, for Avalon Pharmaceuticals, Inc.; or Investors: Chad Rubin of The Trout Group LLC, +1-212-477-9007, ext. 47, for Avalon Pharmaceuticals, Inc. Web site: http://www.avalonrx.com/

Copyright